Carregant...
Recombinant human factor VIIa (rFVIIa) in hemophilia: mode of action and evidence to date
Recombinant activated factor VII (rFVIIa) is a bypassing agent widely used both in the treatment and prevention of hemorrhagic complications due to hemophilia with inhibitor. In such cases, antihemophilic factors cannot be used. The normal physiology of factor VII/ factor VIIa (FVII/FVIIa) in the he...
Guardat en:
| Publicat a: | Ther Adv Hematol |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
SAGE Publications
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5703115/ https://ncbi.nlm.nih.gov/pubmed/29204261 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620717737701 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|